IL33 and asthma: The discovery of epithelial cytokines (alarmins) in the context of asthma, IL-25, TSLP, and IL-33, has demonstrated that they play a significant role in triggering type 2-high type 2 inflammation in the airways and has the potential to be targeted for the development of next-generation biologic drugs for the treatment of asthma [123,124,125,126].